Effects of venetoclax, a BCL2 inhibitor, in systemic chronic active Epstein-Barr virus disease

Effects of venetoclax, a BCL2 inhibitor, in systemic chronic active Epstein-Barr virus disease

Abstract Systemic chronic active Epstein-Barr virus disease (sCAEBV) is a chemotherapy-resistant, EBV-positive T- or NK-cell lymphoproliferative disorder characterized by persistent systemic inflammation driven by the activation of EBV-infected cells. In this study, we explored BCL2, an anti-apoptot...

Full description

Saved in:
Bibliographic Details
Main Authors: Ayaka Ohashi, Miwako Nishio, Mayumi Yoshimori, Kaoru Koike, Morito Kurata, Hayato Tamai, Ken-Ichi Imadome, Ayako Arai
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Venetoclax
BCL2
Systemic chronic active Epstein-Barr virus disease
sCAEBV
EBV
Online Access:https://doi.org/10.1038/s41598-025-03719-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-03719-9

Similar Items